
Among men receiving early androgen deprivation therapy for biochemical recurrence after radical prostatectomy, obesity appears to be a significant risk factor for poorer prognosis.

Among men receiving early androgen deprivation therapy for biochemical recurrence after radical prostatectomy, obesity appears to be a significant risk factor for poorer prognosis.

Tubularized urethras can be engineered from autologous cells and used successfully in the reconstruction of complex posterior urethral defects in children to maintain function long-term.

Urologists say they don't have time to participate in blogs, but some do embrace the medium.

Percutaneous tibial nerve stimulation is not a cost-effective means of treating overactive bladder as a primary intervention, but cost is not the only factor to consider when confronting OAB, and cost alone may not be a sufficient reason to avoid the therapy.

A prospective, randomized, double-blind study comparing postoperative pain between robot-assisted laparoscopic radical prostatectomy and laparoscopic radical prostatectomy appears to favor the robotic technique.

It's d?j? vu all over again with physician-hospital affiliations emerging across the country.

The non-medical use of prescription drugs is thought to represent the fastest growing drug problem in the United States, and urologists aren't immune to it.

Prostate cancer risk declines significantly in men who have a favorably low calcium-absorption genotype and low calcium intake.

The Patient Protection and Affordable Care Act, the new health care reform law, takes some "paltry steps" toward improving the quality of medical care, but it ignores the most fundamental problem that still begs for a solution-how to fairly compensate physicians who treat Medicare patients.

It is important to be cautious when discarding important documents that could be required by the IRS in the event of an audit or would enable you to collect a future refund should you need to file an amended tax return.

Updated phase III clinical trial results provide further evidence that oral abiraterone acetate (ZYTIGA), which was recently approved by the FDA, is well tolerated and has significant clinical benefit in men failing previous intervention for metastatic castration-resistant prostate cancer.

Women with IC symptoms are not getting the diagnosis and treatment they need, despite serious effects on quality of life.

French researchers aiming to develop image-guided laser interstitial thermotherapy for prostate cancer have successfully created a 3-D numerical simulation method for accurately estimating the thermal effects and tissue damage caused by the procedure.

Urologists acknowledged that they do get frustrated with certain patient behaviors, with noncompliance heading the list.

If the trends currently in motion continue, you will see the beginning of accountable care organizations in 2012, with increasing numbers of them year by year, unless there is a repeal of the shared savings portion of the Affordable Care Act or the final rule restricts the potential savings that can be obtained by any ACO.

Early experience indicates laser photoselective vaporization prostatectomy using the latest generation of a 532-nm lithium triborate laser is a safe, efficacious, and efficient treatment for lower urinary tract symptoms secondary to BPH.

Men with clinically localized prostate cancer who undergo radical retropubic prostatectomy with bilateral pelvic lymph node dissection show a higher than expected incidence of lymph node metastases, but men with nodal involvement have excellent 10-year clinical recurrence-free survival.

No fully accepted mechanism of action has been accepted to explain the unusual dossier that PDE-5 inhibitors exhibit in male LUTS.

The phosphodiesterase type-5 inhibitor tadalafil (Cialis) significantly improves erectile function as well as symptoms of BPH/lower urinary tract symptoms in men with both ED and BPH.


Even considering the weight of many unknown variables such as the costs of operating room nursing and equipment replacement, it appears that costs for photoselective vaprization of the prostate (PVP) for BPH are substantially less than those seen with transurethral resection of the prostate (TURP).

Active surveillance may be a viable short-term treatment option in select patients with small renal masses, say researchers from Fox Chase Cancer Center, Philadelphia.

Ten-year data from an international registry-based multicenter study showed that 83% of patients with localized prostate cancer had no biopsy evidence of disease after treatment with high-intensity focused ultrasound (HIFU).

Patients with small kidney tumors are more likely to be offered treatment options based on surgeons? case volume and type of practice than on tumor characteristics, suggests a study by researchers from Mayo Clinic, Rochester, MN.

In men undergoing transrectal ultrasound-guided prostate biopsy (TRUSP), targeted antimicrobial prophylaxis based on findings from rectal swab cultures significantly reduces the incidence of infectious complications and has implications for decreasing the overall cost of care, according to data reported by researchers from Northwestern University, Chicago.

Results from a retrospective review reveal that microsurgical subinguinal varicocelectomy increases serum testosterone levels in men with clinically palpable varicoceles, regardless of varicocele grade.

Men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) can be do-it-yourselfers when it comes to treating the myofascial component of their pain. And that may mean that the men with a phenotype of muscle tenderness?which may be 60% of CP/CPPS patients?could get significant relief and save money.

A new technique for meshless cystocele repair could avoid the shortcomings seen with traditional mesh placement, say researchers from the UCLA School of Medicine.

The 5-alpha-reductase inhibitor dutasteride (Avodart) is associated with markedly lower BPH-related complication rates than the alpha-blocker tamsulosin (Flomax), according to a post hoc analysis of two large clinical trials of these agents presented yesterday.

The selective beta3-adrenoceptor agonist mirabegron effectively improves symptoms of overactive bladder and is very safe and well tolerated, according to results of a North American phase III study presented yesterday.